NUVB Nuvation Bio (NUVB) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001811063
Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
150
13F, latest reported quarter
Conversions, 180 days
7
Codes C/M, not in net · $791.1K priced
What the filings say about NUVB
Insiders, 180 days
-$2.0M net sold
1 buyer · 4 sellers · 25% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$696.0K
1 notice
Nuvation Bio insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Nuvation Bio Inc. insiders sold a net $2.0M of stock across 62 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Nov 20, 2025.
- No other insider sold within 30 days.
- 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF SCIENTIFIC OFFICER Hattersley Gary sold about $709.2K of NUVB under a 10b5-1 plan on Aug 19, 2026; 150 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 18, 2025.
- The trade is 383.5% of the 32,591 shares held after it.
- 2 other insiders sold within 30 days.
- 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF PEOPLE OFFICER Markel Stacy sold about $753.8K of NUVB on Jun 23, 2026; 2 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (2 buys, 2 sales), the last on Apr 17, 2026.
- The trade is 118.9% of the 53,000 shares held after it.
- 2 other insiders sold within 30 days.
- 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF REGULATORY OFFICER Wentworth Kerry sold about $379.3K of NUVB on Jun 23, 2026; 2 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jun 17, 2025.
- +76.8% median (+76.8% mean) 90-day return after 2 previous buys.
- The trade is 376.1% of the 12,673 shares held after it.
- 2 other insiders sold within 30 days.
- 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Sauvage Philippe sold about $286.5K of NUVB on Jun 23, 2026; 2 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Apr 1, 2025.
- +19.4% median (+19.4% mean) 90-day return after 2 previous buys.
- The trade is 11.1% of the 225,000 shares held after it.
- No other insider bought within 30 days.
- 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Mashal Robert bought about $118.3K of NUVB on Jun 9, 2026; 150 funds added in the latest 13F quarter.62 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$2.0M over 180 days
-$709.2K over 90 days
below 70% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
150 funds bought in last quarter
more than 81% of Pharma & Biotech
Revenue
+699.0% year over year
more than 95% of Pharma & Biotech
Margin
-325.3% net margin
below 73% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
22.3% of the float short (float per yahoo 2026-10-26) · 13.9 days to cover · settled 2026-09-30
more than 89% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NUVB
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+2.7%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NUVB: institutional holders (13F)
13F holdings, latest reported quarter
52,230,295 sh
$296.7M
27,630,837 sh
$156.9M
25,954,439 sh
$147.4M
11,919,514 sh
$67.7M
8,081,089 sh
$45.9M
Congress trades in NUVB
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NUVB planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
GARY HATTERSLEY
Filed 2026-08-19
$696.0K
PHILIPPE SAUVAGE
Filed 2026-06-23
$274.6K
STACY MARKEL
Filed 2026-06-23
$720.0K
KERRY WENTWORTH
Filed 2026-06-23
$362.9K
NUVB mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Tanaka Growth Fund
$2.3M position · as of 2026-05-31
5.8%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$8.1M position · as of 2026-06-30
1.9%
PROFUND VP PHARMACEUTICALS
$211.4K position · as of 2026-06-30
1.8%
iShares Genomics Immunology and Healthcare ETF
$3.4M position · as of 2026-07-31
1.8%
Virtus Biotech Etf
$1.7M position · as of 2026-07-31
1.8%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$324.6K position · as of 2026-07-31
1.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
18 registered trials, 9 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
7
Phase 1
1 active
4
Phase 2
3 active
4
Phase 3
4 active
1
Not applicable
0 active
2
Multi-phase
1 active
What changed recently
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Dis
2026-10-21 · Not Yet Recruiting → Recruiting
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.0M sold by insiders over 180 days, 150 funds added last quarter, $696.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
NUVB financials
Revenue growth
+699.0%
XBRL, annual
Net margin
-325.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$169.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM NUVB
| FY Dec 2025 | $62.9M |
| FY Dec 2024 | $7.9M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $31.7M |
| Mar 2026 | $83.2M |
| Dec 2025 | $41.9M |
| Sep 2025 | $13.1M |
| Jun 2025 | $4.8M |
| Mar 2025 | $3.1M |
| Dec 2024 | $5.7M |
| Sep 2024 | $727.0K |
At each fiscal year end
Single quarter
Net margin, TTM
-88.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM NUVB
| FY Dec 2025 | -325.3% |
| FY Dec 2024 | -7,214% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -198.3% |
| Mar 2026 | +6.5% |
| Dec 2025 | -87.4% |
| Sep 2025 | -425.2% |
| Jun 2025 | -1,221% |
| Mar 2025 | -1,726% |
| Dec 2024 | -865.8% |
| Sep 2024 | -5,669% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$128.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM NUVB
| FY Dec 2025 | -$181.4M |
| FY Dec 2024 | -$130.4M |
| FY Dec 2023 | -$68.1M |
| FY Dec 2022 | -$96.5M |
| FY Dec 2021 | -$68.5M |
| Jun 2026 | -$43.2M |
| Mar 2026 | $5.0M |
| Dec 2025 | -$29.7M |
| Sep 2025 | -$60.6M |
| Jun 2025 | -$48.4M |
| Mar 2025 | -$42.7M |
| Dec 2024 | -$46.3M |
| Sep 2024 | -$31.1M |
At each fiscal year end
Single quarter
Debt to equity
0.98x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity NUVB
| FY Dec 2025 | 0.17x |
| FY Dec 2024 | 0.01x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.98x |
| Mar 2026 | 0.17x |
| Dec 2025 | 0.17x |
| Sep 2025 | 0.16x |
| Jun 2025 | 0.14x |
| Mar 2025 | 0.01x |
| Dec 2024 | 0.01x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.48x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt NUVB
| FY Dec 2025 | -3.28x |
| FY Dec 2024 | -20.76x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.48x |
| Mar 2026 | -2.37x |
| Dec 2025 | -3.28x |
| Sep 2025 | -3.60x |
| Jun 2025 | -3.20x |
| Mar 2025 | -27.68x |
| Dec 2024 | -20.76x |
| Sep 2024 | -11.77x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-47.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity NUVB
| FY Dec 2025 | -53.2% |
| FY Dec 2024 | -106.3% |
| FY Dec 2023 | -12.0% |
| FY Dec 2022 | -14.9% |
| FY Dec 2021 | -18.1% |
| Jun 2026 | -47.8% |
| Mar 2026 | -39.5% |
| Dec 2025 | -53.2% |
| Sep 2025 | -52.5% |
| Jun 2025 | -64.4% |
| Mar 2025 | -119.7% |
| Dec 2024 | -106.3% |
| Sep 2024 | -95.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-21.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NUVB
| FY Dec 2025 | -36.0% |
| FY Dec 2024 | -97.7% |
| FY Dec 2023 | -11.7% |
| FY Dec 2022 | -14.4% |
| FY Dec 2021 | -17.4% |
| Jun 2026 | -21.5% |
| Mar 2026 | -26.5% |
| Dec 2025 | -36.0% |
| Sep 2025 | -37.1% |
| Jun 2025 | -32.7% |
| Mar 2025 | -109.7% |
| Dec 2024 | -97.7% |
| Sep 2024 | -88.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital NUVB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-22.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NUVB
| FY Dec 2025 | -42.8% |
| FY Dec 2024 | -108.7% |
| FY Dec 2023 | -15.8% |
| FY Dec 2022 | -16.9% |
| FY Dec 2021 | -19.2% |
| Jun 2026 | -22.2% |
| Mar 2026 | -31.0% |
| Dec 2025 | -42.8% |
| Sep 2025 | -44.5% |
| Jun 2025 | -40.0% |
| Mar 2025 | -121.8% |
| Dec 2024 | -108.7% |
| Sep 2024 | -99.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing NUVB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.6B
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value NUVB
| FY Dec 2025 | $3.0B |
| FY Dec 2024 | $865.8M |
| FY Dec 2023 | $288.0M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $2.0B |
| Mar 2026 | $1.4B |
| Dec 2025 | $3.0B |
| Sep 2025 | $1.2B |
| Jun 2025 | $468.1M |
| Mar 2025 | $550.1M |
| Dec 2024 | $865.8M |
| Sep 2024 | $549.2M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-8.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield NUVB
| FY Dec 2025 | -5.9% |
| FY Dec 2024 | -14.6% |
| FY Dec 2023 | -20.6% |
| FY Dec 2022 | -23.0% |
| FY Dec 2021 | -3.7% |
| Jun 2026 | -6.5% |
| Mar 2026 | -9.1% |
| Dec 2025 | -5.9% |
| Sep 2025 | -15.6% |
| Jun 2025 | -25.4% |
| Mar 2025 | -26.6% |
| Dec 2024 | -14.6% |
| Sep 2024 | -17.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing NUVB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $62.9M | $7.9M | $0 | n/a |
| Gross profit | n/a | $795.0K | $0 | n/a |
| Operating income | -$213.1M | -$592.6M | -$99.8M | -$119.7M |
| Net income | -$204.6M | -$567.9M | -$75.8M | -$104.2M |
| EPS (diluted) | -0.60 | -2.11 | -0.35 | -0.48 |
| Operating cash flow | -$173.4M | -$130.4M | -$68.0M | -$96.1M |
| Cash | $164.1M | $35.7M | $42.6M | $101.1M |
| Long-term debt | $47.2M | $0 | n/a | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
NUVB Stock Sonar score 6/7 axes
Find similar shapesCompareNUVB ranks highest on growth (95th percentile) and profitability (64th), and lowest on risk and compliance (18th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NUVB filings, in plain words
Are Nuvation Bio insiders buying or selling NUVB?
In the 180 days to 2026-10-28, Nuvation Bio insiders were net sellers, a net $2.0M: $118.3K of purchases and $2.1M of sales reported on Form 4, by 1 buyer and 4 sellers.
Are there planned insider sales of NUVB?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $696.0K of stock; the latest, by GARY HATTERSLEY, was filed 2026-08-19.
Read the full summary
In the 180 days to 2026-10-28, Nuvation Bio insiders were net sellers of NUVB, a net $2.0M across purchases and sales reported on Form 4 by 1 buyer and 4 sellers. Sales outweighed purchases more than tenfold by value. 25% of the 4 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $696.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
